In SCLC, inhibition of LSD1 by the selective inhibitor ORY‐1001 activates the NOTCH pathway, resulting in the upregulation of NOTCH1, NOTCH2, REST, and HES1. This evidence concerns the gene REST and small cell lung carcinoma.